Most Read This Week
- Comparison Between Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting TB
- Efficacy of Nirmatrelvir in the Treatment of Vaccinated or Unvaccinated Adult Outpatients With COVID-19
- Impact of BMI on Long-Term Survival After ICU Admission for COVID-19
- Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
- Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Adults Hospitalized in the US
Recently Updated
- Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
- RSV Burden in Children Under 5 Increased in 2021 and 2022 Versus 2015-2019
- Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor Among Patients With Cystic Fibrosis and Advanced Lung Disease
- Trends in the US Medical Cannabis Registrations, Authorizing Clinicians, and Reasons for Use Between 2020 and 2022
- State Medicaid Coverage for Tobacco Cessation Treatments and Barriers to Accessing Treatments in the US Between 2018 and 2022